SCHEMBL7715674

SCHEMBL7715674

CC(=O)NCCCCCNC(=O)OC(C)(C)C

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.73
MAOA P21397 1/20 0.63
MAOB P27338 1/20 0.63
KDM4E B2RXH2 1/20 0.61
MAPK1 P28482 1/20 0.61
HIF1A Q16665 1/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GAA P10253 1/20 0.59
CA12 O43570 6/20 0.58
CA1 P00915 6/20 0.58
CA2 P00918 6/20 0.58
CA9 Q16790 6/20 0.58
PAOX Q6QHF9 3/20 0.52
ADRA1A P35348 1/20 0.50
EPHX1 P07099 1/20 0.46
CYP3A4 P08684 1/20 0.45
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16979083 1.00 TDP1 (0.73) TDP1MAOAMAOBKDM4EMAPK1
SCHEMBL13888625 0.98 TDP1 (0.70) TDP1MAOAMAOBKDM4EMAPK1
SCHEMBL1629518 0.94 TDP1 (0.65) TDP1MAOAMAOBKDM4EMAPK1
SCHEMBL5162656 0.92 TDP1 (0.85) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL343629 0.92 TDP1 (0.85) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL3025184 0.92 TDP1 (0.85) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL136815 0.92 TDP1 (0.85) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL137629 0.92 TDP1 (0.85) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL134329 0.92 TDP1 (0.85) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL140853 0.92 TDP1 (0.85) TDP1MAOAMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023242598-A1 BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2023-12-21 WO disclosed
US-8431529-B2 Bi-dentate compounds as kinase inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-04-30 US disclosed
US-8431529-B2 Bi-dentate compounds as kinase inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-04-30 US disclosed
US-20110172164-A1 BI-DENTATE COMPOUNDS AS KINASE INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-07-14 US disclosed
US-7919581-B2 Bi-dentate compounds as kinase inhibitors BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2011-04-05 US disclosed
US-20090054348-A1 BI-DENTATE COMPOUNDS AS KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-02-26 US disclosed
WO-2009018490-A1 BI-DENTATE COMPOUNDS AS KINASE INHIBITORS BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2009-02-05 WO disclosed
US-6376548-B1 FUNGICIDES; HERBICIDES; INSECTICIDES ROHM AND HAAS COMPANY 2002-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172164-A1 BI-DENTATE COMPOUNDS AS KINASE INHIBITORS MAP2K2, MAP2K7, MAP2K1 TDP1 2907/4885MAOA 3665/4885MAOB 3705/4885
US-20090054348-A1 BI-DENTATE COMPOUNDS AS KINASE INHIBITORS MAP2K2, MAP2K1, MAP2K7 TDP1 3097/4885MAOA 3439/4885MAOB 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.